| scholarly article | Q13442814 |
| P50 | author | Christine E Brown | Q59680493 |
| P2093 | author name string | Xin Yang | |
| Behnam Badie | |||
| Stephen J Forman | |||
| Massimo D'Apuzzo | |||
| James F Sanchez | |||
| Brenda Chang | |||
| Wen-Chung Chang | |||
| Renate Starr | |||
| Alfonso Brito | |||
| Aniee Sarkissian | |||
| Brenda Aguilar | |||
| Lihong Weng | |||
| Michael E Barish | |||
| Julie R Ostberg | |||
| P2860 | cites work | Trafficking of T cells into tumors | Q38283501 |
| The pharmacology of second-generation chimeric antigen receptors. | Q38541019 | ||
| Characterization and Functional Analysis of scFv-based Chimeric Antigen Receptors to Redirect T Cells to IL13Rα2-positive Glioma. | Q38823847 | ||
| Immune reactivity in the nervous system: modulation of T-lymphocyte activation by glial cells. | Q39691028 | ||
| Medulloblastomas expressing IL13Ralpha2 are targets for IL13-zetakine+ cytolytic T cells. | Q40070837 | ||
| Tumor-derived chemokine MCP-1/CCL2 is sufficient for mediating tumor tropism of adoptively transferred T cells. | Q40091300 | ||
| Expression of interleukin-13 receptor alpha2 in glioblastoma multiforme: implications for targeted therapies | Q40177093 | ||
| T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial | Q40186710 | ||
| Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells. | Q40479866 | ||
| Human T lymphocyte genetic modification with naked DNA. | Q40863205 | ||
| T cells redirected to interleukin-13Rα2 with interleukin-13 mutein--chimeric antigen receptors have anti-glioma activity but also recognize interleukin-13Rα1 | Q42114926 | ||
| Serial transfer of single-cell-derived immunocompetence reveals stemness of CD8(+) central memory T cells | Q42205546 | ||
| Retargeting interleukin 13 for radioimmunodetection and radioimmunotherapy of human high-grade gliomas | Q42612665 | ||
| Successful treatment of melanoma brain metastases with adoptive cell therapy. | Q42933679 | ||
| Human B lymphocytes immortalization by Epstein-Barr virus in the presence of cyclosporin A. | Q45835799 | ||
| Autologous HER2 CMV bispecific CAR T cells are safe and demonstrate clinical benefit for glioblastoma in a Phase I trial | Q45893712 | ||
| Interleukin-13 receptor alpha 2, EphA2, and Fos-related antigen 1 as molecular denominators of high-grade astrocytomas and specific targets for combinatorial therapy | Q46825509 | ||
| Anti-CD19 CAR T Cells in CNS Diffuse Large-B-Cell Lymphoma | Q47915164 | ||
| Receptor for interleukin 13 is a marker and therapeutic target for human high-grade gliomas | Q48195495 | ||
| Analysis of the aphthovirus 2A/2B polyprotein ‘cleavage’ mechanism indicates not a proteolytic reaction, but a novel translational effect: a putative ribosomal ‘skip’ | Q64410654 | ||
| Noninvasive detection of therapeutic cytolytic T cells with 18F-FHBG PET in a patient with glioma | Q24598366 | ||
| Novel immunotherapies in lymphoid malignancies | Q26777394 | ||
| CD19 CAR Therapy for Acute Lymphoblastic Leukemia | Q28083750 | ||
| Glucocorticoid hormone-induced modulation of gene expression and regulation of T-cell death: role of GITR and GILZ, two dexamethasone-induced genes | Q28142750 | ||
| Proteomics. Tissue-based map of the human proteome | Q29617248 | ||
| Chimeric antigen receptor T cells for sustained remissions in leukemia | Q29617588 | ||
| Chimeric antigen receptor-modified T cells for acute lymphoid leukemia | Q29620130 | ||
| CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009. | Q30447832 | ||
| Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy | Q33561644 | ||
| Corticosteroids in brain cancer patients: benefits and pitfalls | Q34191990 | ||
| Engraftment of human central memory-derived effector CD8+ T cells in immunodeficient mice | Q34667739 | ||
| Glioma IL13Rα2 is associated with mesenchymal signature gene expression and poor patient prognosis | Q35035593 | ||
| Suppression of human glioma xenografts with second-generation IL13R-specific chimeric antigen receptor-modified T cells | Q35111932 | ||
| Costimulation of T cells by OX40, 4-1BB, and CD27. | Q35145627 | ||
| Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity | Q35216278 | ||
| Chimeric antigen receptors with mutated IgG4 Fc spacer avoid fc receptor binding and improve T cell persistence and antitumor efficacy | Q35399080 | ||
| Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates | Q36183567 | ||
| Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma. | Q36248008 | ||
| Phenotypic and functional attributes of lentivirus-modified CD19-specific human CD8+ central memory T cells manufactured at clinical scale | Q36475411 | ||
| Cutting edge: IL-13Rα1 expression in dopaminergic neurons contributes to their oxidative stress-mediated loss following chronic peripheral treatment with lipopolysaccharide | Q36533944 | ||
| Stem-like tumor-initiating cells isolated from IL13Rα2 expressing gliomas are targeted and killed by IL13-zetakine-redirected T Cells | Q36626774 | ||
| IL-13 receptor isoforms: breaking through the complexity | Q36909673 | ||
| CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients | Q36951727 | ||
| Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape | Q37137932 | ||
| Regional CAR-T cell infusions for peritoneal carcinomatosis are superior to systemic delivery | Q37497357 | ||
| The blood-brain barrier and immune function and dysfunction | Q37576216 | ||
| Reporter gene imaging of targeted T cell immunotherapy in recurrent glioma. | Q37603380 | ||
| CD19-CAR trials | Q37692134 | ||
| Antibody-modified T cells: CARs take the front seat for hematologic malignancies | Q37723469 | ||
| Standard of care therapy for malignant glioma and its effect on tumor and stromal cells | Q37930388 | ||
| Significance of interleukin-13 receptor alpha 2-targeted glioblastoma therapy. | Q38203856 | ||
| P433 | issue | 1 | |
| P304 | page(s) | 31-44 | |
| P577 | publication date | 2017-10-05 | |
| P1433 | published in | Molecular Therapy | Q15762400 |
| P1476 | title | Optimization of IL13Rα2-Targeted Chimeric Antigen Receptor T Cells for Improved Anti-tumor Efficacy against Glioblastoma | |
| P478 | volume | 26 |
| Q64040883 | Adeno-associated virus vector as a platform for gene therapy delivery |
| Q89128658 | Advances in the use of natural receptor- or ligand-based chimeric antigen receptors (CARs) in haematologic malignancies |
| Q54979818 | Advances on chimeric antigen receptor-modified T-cell therapy for oncotherapy. |
| Q90677062 | CAR T Cell Therapy Progress and Challenges for Solid Tumors |
| Q99730742 | CAR T Cell Therapy for Solid Tumors: Bright Future or Dark Reality? |
| Q92245332 | CAR T cells for brain tumors: Lessons learned and road ahead |
| Q52658445 | CAR T-cell therapy for glioblastoma: ready for the next round of clinical testing? |
| Q91670709 | CAR-Engineered NK Cells for the Treatment of Glioblastoma: Turning Innate Effectors Into Precision Tools for Cancer Immunotherapy |
| Q90051519 | Chlorotoxin-directed CAR T cells for specific and effective targeting of glioblastoma |
| Q64267591 | Clinical chimeric antigen receptor-T cell therapy: a new and promising treatment modality for glioblastoma |
| Q60046462 | Current Options and Future Directions in Immune Therapy for Glioblastoma |
| Q52344613 | Current Strategies to Enhance Anti-Tumour Immunity. |
| Q55457323 | Current state of immunotherapy for glioblastoma. |
| Q59795144 | Effective Targeting of TAG72 Peritoneal Ovarian Tumors via Regional Delivery of CAR-Engineered T Cells |
| Q100751371 | Endothelial, pericyte and tumor cell expression in glioblastoma identifies fibroblast activation protein (FAP) as an excellent target for immunotherapy |
| Q67201058 | Gene editing for immune cell therapies |
| Q57048305 | Genetic Abnormalities, Clonal Evolution, and Cancer Stem Cells of Brain Tumors |
| Q61811641 | Genetically Engineered T-Cells for Malignant Glioma: Overcoming the Barriers to Effective Immunotherapy |
| Q47553080 | Glioblastoma under Siege: An Overview of Current Therapeutic Strategies. |
| Q55358019 | Glioblastoma-targeted CD4+ CAR T cells mediate superior antitumor activity. |
| Q101476400 | IL-6 trans-signaling promotes the expansion and anti-tumor activity of CAR T cells |
| Q92486992 | IL15 Enhances CAR-T Cell Antitumor Activity by Reducing mTORC1 Activity and Preserving Their Stem Cell Memory Phenotype |
| Q92592521 | Impact of pre-therapy glioblastoma multiforme microenvironment on clinical response to autologous CMV-specific T-cell therapy |
| Q92438272 | In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function |
| Q93271206 | Locoregional delivery of CAR T cells to the cerebrospinal fluid for treatment of metastatic medulloblastoma and ependymoma |
| Q92639482 | Mathematical deconvolution of CAR T-cell proliferation and exhaustion from real-time killing assay data |
| Q92150199 | Mechanisms of resistance to CAR T cell therapy |
| Q93088940 | Neural Stem Cells of the Subventricular Zone as the Origin of Human Glioblastoma Stem Cells. Therapeutic Implications |
| Q94467230 | New directions in chimeric antigen receptor T cell [CAR-T] therapy and related flow cytometry |
| Q92120527 | Preventive infusion of donor-derived CAR-T cells after haploidentical transplantation: Two cases report |
| Q58117045 | Receptor-Targeted Glial Brain Tumor Therapies |
| Q92354027 | The Evolving Protein Engineering in the Design of Chimeric Antigen Receptor T Cells |
| Q90641415 | The blood-brain barrier and blood-tumour barrier in brain tumours and metastases |
| Q92633429 | The making and function of CAR cells |
Search more.